Showing 1 - 10 of 20 Urinary Tract, Sexual Organs,
A Double-blind, Randomized, Controlled Dose Escalation Trial of Autologous Mesenchymal Stromal Cells in Living Donor Kidney Transplant Recipients

Status: Enrolling

Investigator: Ahmed Gaber

Study Coordinator:

Phone:

Kidney transplantation is a good treatment option for people with kidney disease. However, there is still much to learn about how to best care for the transplanted kidney and keep it functioning for a long time. Transplant recipients receive ind ... Read more >

A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation

Status: Enrolling

Investigator: Ahmed Gaber

Study Coordinator: Jack Curtis

Phone: 913.486.9249

This is a randomized, double-blind, placebo-controlled trial in de novo kidney transplant patients to determine if the addition of fingolimod (brand name Gilenya®, candidate name- FTY720) on the background of standard immunosuppression will prev ... Read more >

A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Status: Enrolling

Investigator: Pedro Ramirez

Study Coordinator: Jaya Kamath

Phone: 713.441.6616

The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evalua ... Read more >

A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum (GOG-3026)

Status: Open Not Enrolling

Investigator: Aparna Kamat

Study Coordinator: Jaya Kamath

Phone: 713.441.6616

The study evaluates the response to treatment with Ribociclib and Letrozole in patients with recurrent low grade serous cancer of the ovary, fallopian tube or peritoneum. ... Read more >

A Phase III Randomised Clinical Trial Comparing Sentinel Node Biopsy With No Retroperitoneal Node Dissection in Apparent Early-Stage Endometrial Cancer

Status: Enrolling

Investigator: Behrouz Zand

Study Coordinator: Jaya Kamath

Phone: 713.441.6616

Endometrial cancer (EC) is the most common gynaecological cancer. Current treatment of EC typically includes removal of the uterus and to determine the extent of the disease (removal of fallopian tubes, ovaries & if required a lymph node dissect ... Read more >

A phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naive, High Grade Non-Muscle Invasive Bladder Cancer.

Status: Open Not Enrolling

Investigator: Raj Satkunasivam

Study Coordinator: Taliah Muhammad

Phone: 346.238.4523

This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating patients with bladder ... Read more >

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3)

Status: Open Not Enrolling

Investigator: Eleni Efstathiou

Study Coordinator:

Phone:

The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse. Participation may last approximately 60 months. ... Read more >

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (RAMP 301)

Status: Enrolling

Investigator: Aparna Kamat

Study Coordinator: Jaya Kamath

Phone: 713.441.6616

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.</div ... Read more >

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/?TroFuse-020/?Gog-3101/?ENGOT-cx20)

Status: Enrolling

Investigator: Pedro Ramirez

Study Coordinator: Jaya Kamath

Phone: 713.441.6616

This study will have two phases: a sacituzumab tirumotecan safety run-in and a Phase 3 portion. The safety run-in phase will be used to evaluate the efficacy and safety of sacituzumab tirumotecan at the dose for evaluation in the Phase 3 portion ... Read more >

An Open-Label, Controlled, Randomized Phase 3 Trial Evaluating 12-Month Kidney Function in Highly Sensitized (cPRA =99.9%) Kidney Transplant Patients with Positive Crossmatch Against a Deceased Donor, Using Imlifidase with Standard of Care

Status: Open Not Enrolling

Investigator: Ahmed Gaber

Study Coordinator: Beatriz Efron

Phone: 713.363.8890

An open-label, controlled, randomized Phase 3 trial evaluating 12-month kidney function in highly sensitized (cPRA =99.9%) kidney transplant patients with positive crossmatch against a deceased donor, comparing desensitization using imlifidase w ... Read more >

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

Status: Enrolling

Investigator: Pedro Ramirez

Study Coordinator: Jaya Kamath

Phone: 713.441.6616

This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy before and after surgery (neoadjuvant chemo ... Read more >

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

Status: Open Not Enrolling

Investigator: Tarrik Zaid

Study Coordinator: Jaya Kamath

Phone: 713.441.6616

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. ... Read more >

Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer Using an External Control Arm (ARASEC)

Status: Open Not Enrolling

Investigator: Eleni Efstathiou

Study Coordinator: Gabrielle Hayes

Phone: 734.415.918

This is a phase 2 open label single arm study using an external control arm, to assess if the addition of darolutamide to ADT provides superior efficacy in terms of progression-free survival (PFS), as compared to ADT alone for men diagnosed with ... Read more >

Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial

Status: Enrolling

Investigator: Monisha Singh

Study Coordinator: Jaya Kamath

Phone: 713.441.6616

This phase II ComboMATCH treatment trial evaluates the effectiveness of palbociclib and binimetinib in treating patients with RAS-mutated cancers. Palbociclib and binimetinib are both in a class of medications called kinase inhibitors. They work ... Read more >

Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy

Status: Open Not Enrolling

Investigator: Eleni Efstathiou

Study Coordinator: Gabrielle Hayes

Phone: 734.415.918

This is an international, multi-center, open-label, phase II study in patients with metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1 /PD-L1 based immunotherapy. At least 140 patients are anticipated to be enrolle ... Read more >

Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Status: Open Not Enrolling

Investigator: Eleni Efstathiou

Study Coordinator: Gabrielle Hayes

Phone: 734.415.918

The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. ... Read more >

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) (TroFuse-005)

Status: Enrolling

Investigator: Pedro Ramirez

Study Coordinator: Jaya Kamath

Phone: 713.441.6616

Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with platinum based therapy (a type of chemotherapy) and immunotherapy. Immunotherapy is a treatment that helps the immune s ... Read more >

Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)

Status: Enrolling

Investigator: Eleni Efstathiou

Study Coordinator: Gabrielle Hayes

Phone: 734.415.918

This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD5305 when given in combination with new hormonal agents (NHAs) in patients with Metastatic Prostate Cancer. ... Read more >

Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (CREST)

Status: Open Not Enrolling

Investigator: Raj Satkunasivam

Study Coordinator: Taliah Muhammad

Phone: 346.238.4523

Primary Purpose: Treatment ... Read more >

Testing the Addition of Trastuzumab or Trastuzumab/?Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Cancer

Status: Enrolling

Investigator: Aparna Kamat

Study Coordinator: Jaya Kamath

Phone: 713.441.6616

This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta [TM]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo [TM]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumor ... Read more >